What is the price-to-earnings ratio of Elan?
The price-earnings ratio of Elan is currently 17.66.
Elan P/E 2024
Elan P/E
17.66
Ticker
6099.T
ISIN
JP3167680002
WKN
A12C13
As of Dec 1, 2024, Elan's P/E ratio was 17.66, a -13.85% change from the 20.5 P/E ratio recorded in the previous year.
The Elan P/E history
Elan Aktienanalyse
What does Elan do?
Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Elan's P/E Ratio
The Price to Earnings (P/E) Ratio of Elan is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Elan's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Elan is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Elan’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Elan stock
How has the price-earnings ratio of Elan changed compared to last year?
The price-to-earnings ratio of Elan has increased by -13.85% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Elan high compared to other companies?
Yes, the price-to-earnings ratio of Elan is high compared to other companies.
How does an increase in the price-earnings ratio of Elan affect the company?
An increase in the price-earnings ratio of Elan would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Elan affect the company?
A decrease in the price-earnings ratio of Elan would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Elan?
Some factors that influence the price-earnings ratio of Elan are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Elan pay?
Over the past 12 months, Elan paid a dividend of 13 JPY . This corresponds to a dividend yield of about 1.93 %. For the coming 12 months, Elan is expected to pay a dividend of 15.09 JPY.
What is the dividend yield of Elan?
The current dividend yield of Elan is 1.93 %.
When does Elan pay dividends?
Elan pays a quarterly dividend. This is distributed in the months of January, January, January, January.
How secure is the dividend of Elan?
Elan paid dividends every year for the past 13 years.
What is the dividend of Elan?
For the upcoming 12 months, dividends amounting to 15.09 JPY are expected. This corresponds to a dividend yield of 2.24 %.
In which sector is Elan located?
Elan is assigned to the 'Health' sector.
Wann musste ich die Aktien von Elan kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Elan from 3/1/2025 amounting to 14 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.
When did Elan pay the last dividend?
The last dividend was paid out on 3/1/2025.
What was the dividend of Elan in the year 2023?
In the year 2023, Elan distributed 11 JPY as dividends.
In which currency does Elan pay out the dividend?
The dividends of Elan are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Elan
Our stock analysis for Elan Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Elan Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
